Medications
FDA panel to weigh revoking key use of Abbott drug
(AP) -- A panel of advisers to the Food and Drug Administration will consider this week whether to revoke a key indication from Abbott's blockbuster cholesterol drug Trilipix.
May 17, 2011
0
0
